Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APS Aptose Biosciences	C$2.22 -0.9%	C$2.03	C$1.02 ▼ C$27.00	C$95.59M	1.36	5,510 shs	1,800 shs
IBT IBEX Technologies	C$1.44	C$1.44	C$0.75 ▼ C$1.45	C$35.54M	-0.05	68,888 shs	200 shs
ONC BeOne Medicines	$294.55 +1.4%	$250.96	$152.81 ▼ $300.00	$31.82B	0.28	355,827 shs	893,521 shs
TH Target Hospitality	$7.59 -2.7%	$7.28	$4.00 ▼ $11.10	$775.04M	1.83	545,512 shs	212,720 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APS Aptose Biosciences	-0.89%	-11.20%	+89.74%	-32.73%	-91.78%
IBT IBEX Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
ONC BeOne Medicines	+1.45%	+17.68%	+16.52%	+27.52%	+29,454,999,900.00%
TH Target Hospitality	-2.69%	-5.24%	+7.20%	+14.31%	-18.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APS Aptose Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBT IBEX Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	2.549 of 5 stars	3.5	0.0	0.0	0.0	3.0	1.7	0.6
TH Target Hospitality	2.8455 of 5 stars	3.4	3.0	0.0	0.0	1.9	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APS Aptose Biosciences	4.00	Strong Buy	N/A	N/A
IBT IBEX Technologies	0.00	N/A	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$327.56	11.21% Upside
TH Target Hospitality	2.75	Moderate Buy	$11.25	48.22% Upside

Current Analyst Ratings Breakdown

Latest IBT, TH, ONC, and APS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
5/8/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/24/2025	ONC BeOne Medicines	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00
4/21/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$311.00 ➝ $317.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APS Aptose Biosciences	N/A	N/A	C$1.39 per share	1.60	C($0.92) per share	N/A
IBT IBEX Technologies	C$5.77M	6.15	C$0.92 per share	1.56	C$0.58 per share	2.48
ONC BeOne Medicines	$3.81B	8.47	N/A	N/A	$34.10 per share	8.64
TH Target Hospitality	$386.27M	1.95	$1.45 per share	5.25	$4.26 per share	1.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APS Aptose Biosciences	-C$154.69M	-C$5.02	N/A	∞	N/A	N/A	1,017.48%	-136.29%	N/A
IBT IBEX Technologies	C$3.10M	C$0.12	11.52	∞	N/A	53.78%	21.95%	6.42%	N/A
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	414.86	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)
TH Target Hospitality	$71.26M	$0.43	17.65	21.08	N/A	12.71%	11.34%	6.94%	8/6/2025 (Estimated)

Latest IBT, TH, ONC, and APS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	TH Target Hospitality	-$0.10	N/A	N/A	N/A	$56.43 million	N/A
5/19/2025	Q1 2025	TH Target Hospitality	-$0.02	-$0.05	-$0.03	-$0.07	$65.37 million	$69.90 million
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APS Aptose Biosciences	N/A	0.39%	N/A	N/A	N/A
IBT IBEX Technologies	N/A	3.11%	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
TH Target Hospitality	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APS Aptose Biosciences	-117.37	1.05	5.41
IBT IBEX Technologies	11.06	6.24	4.93
ONC BeOne Medicines	0.05	1.96	1.71
TH Target Hospitality	0.10	1.97	1.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APS Aptose Biosciences	15.10%
IBT IBEX Technologies	19.05%
ONC BeOne Medicines	48.55%
TH Target Hospitality	32.40%

Insider Ownership

Company	Insider Ownership
APS Aptose Biosciences	17.11%
IBT IBEX Technologies	25.36%
ONC BeOne Medicines	6.62%
TH Target Hospitality	68.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APS Aptose Biosciences	31	43.06 million	N/A	Not Optionable
IBT IBEX Technologies	N/A	24.68 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
TH Target Hospitality	820	99.36 million	31.80 million	Not Optionable

IBT, TH, ONC, and APS Headlines

Recent News About These Companies

Reviewing Target Hospitality (TH) & Its Competitors

July 14, 2025 | americanbankingnews.com

Contrasting Target Hospitality (TH) & Its Peers

July 11, 2025 | americanbankingnews.com

Target Hospitality (TH) vs. Its Competitors Head to Head Review

July 11, 2025 | americanbankingnews.com

Teacher Retirement System of Texas Has $2.94 Million Stock Position in Target Hospitality Corp. (NASDAQ:TH)

July 9, 2025 | marketbeat.com

Target Hospitality (TH) versus Its Rivals Head-To-Head Comparison

July 9, 2025 | americanbankingnews.com

What's Next: Target Hospitality's Earnings Preview

July 8, 2025 | benzinga.com

Target Hospitality Corp. (TH) - Yahoo Finance

July 4, 2025 | finance.yahoo.com

Target Hospitality’s Q1 Earnings Call: Our Top 5 Analyst Questions

July 1, 2025 | msn.com

TH Target Hospitality Corp. - Seeking Alpha

June 28, 2025 | seekingalpha.com

TH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 Outlook

May 30, 2025 | msn.com

Analysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)

May 22, 2025 | theglobeandmail.com

Target Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing Vehicle

May 21, 2025 | prnewswire.com

Target Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call Transcript

May 20, 2025 | insidermonkey.com

Target Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Target Hospitality Corp. (TH) Q1 2025 Earnings Call Transcript

May 19, 2025 | seekingalpha.com

Target Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

May 19, 2025 | msn.com

Target Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

May 19, 2025 | zacks.com

Target Hospitality (TH) Reports Q1 Loss, Tops Revenue Estimates

May 19, 2025 | zacks.com

Target Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth Pipeline

May 19, 2025 | prnewswire.com

Insights into Target Hospitality's Upcoming Earnings

May 16, 2025 | benzinga.com

Here's What to Know Ahead of Target Hospitality's Q1 Earnings

May 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending

IBT, TH, ONC, and APS Company Descriptions

Aptose Biosciences TSE:APS

C$2.22 -0.02 (-0.89%)

As of 07/18/2025 04:10 PM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

IBEX Technologies CVE:IBT

C$1.44 0.00 (0.00%)

As of 04/5/2024

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

BeOne Medicines NASDAQ:ONC

$294.55 +4.20 (+1.45%)

As of 07/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Target Hospitality NASDAQ:TH

$7.59 -0.21 (-2.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$7.56 -0.02 (-0.33%)

As of 07/18/2025 06:30 PM Eastern

Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time